Impact Factor 4.137 | CiteScore 4.28
More on impact ›
The Thoracic Oncology Section of Frontiers in Oncology aims to advance the understanding and treatment of various thoracic malignancies by publishing high quality clinical and translational reports in a timely manner.
The Section has an interest in receiving manuscripts centred on the underlying biology of thoracic malignancies, the changing epidemiology of these diseases, advances in diagnostic sciences, biomarker development and therapeutic approaches of various modalities.
There is particular interest in the increasingly relevant fields of targeted therapy and immunotherapy; we welcome reports outlining novel treatment strategies and those that provide insights into both efficacy and resistance. Case reports will be considered if they offer a unique and clinically useful perspective. Submission of clinical trial reports are also welcome and negative trial results will not preclude consideration. While basic science manuscripts will be considered, the Thoracic Oncology Section is tailored to a clinical and translational audience.
Submissions not in scope for this specialty include those discussing Esophageal Cancers (which can be submitted to the Gastrointestinal Oncology Section of Frontiers in Oncology) and Cardiac Tumors (which can be submitted to the Cardio-Oncology Section of Frontiers in Cardiovascular Medicine).
Indexed in: PubMed, PubMed Central, Scopus, Google Scholar, DOAJ, CrossRef, Chemical Abstracts Service (CAS), Science Citation Index Expanded, CLOCKSS
PMCID: all published articles receive a PMCID
Thoracic Oncology welcomes submissions of the following article types: Case Report, Clinical Trial, Correction, Editorial, General Commentary, Hypothesis and Theory, Methods, Mini Review, Opinion, Original Research, Perspective, Review, Specialty Grand Challenge, Systematic Review and Technology and Code.
All manuscripts must be submitted directly to the section Thoracic Oncology, where they are peer-reviewed by the Associate and Review Editors of the specialty section.
Articles published in the section Thoracic Oncology will benefit from the Frontiers impact and tiering system after online publication. Authors of published original research with the highest impact, as judged democratically by the readers, will be invited by the Chief Editor to write a Frontiers Focused Review - a tier-climbing article. This is referred to as "democratic tiering". The author selection is based on article impact analytics of original research published in all Frontiers specialty journals and sections. Focused Reviews are centered on the original discovery, place it into a broader context, and aim to address the wider community across all of Oncology.
Avenue du Tribunal Fédéral 34
CH – 1005 Lausanne
Tel +41(0)21 510 17 40
Fax +41 (0)21 510 17 01
For all queries regarding manuscripts in Review and potential conflicts of interest, please contact firstname.lastname@example.org
For queries regarding Research Topics, Editorial Board applications, and journal development, please contact email@example.com